ADPH releases list of Ala. facilities that got NECC products
The Alabama Department of Public Health is releasing a list of health care facilities in Alabama that received products included in a third recall from the New England Compounding Center (NECC).
ADPH says the products have no known association with confirmed disease and they have not been proven to be contaminated. Public health officials have notified each facility in order to ensure that NECC products have been removed from their inventory and to discuss the process for contacting their patients.
LIST OF FACILITIES THAT RECEIVED ANY NECC PRODUCT
(List includes second and third recall)
Andalusia Regional Hospital, Andalusia
Northeast Alabama Regional Medical Center, Anniston
Atmore Community Hospital, Atmore
Healthcare Authority for UAB Medical West, Bessemer
Alabama Pain Physicians, Birmingham
Baptist Medical Center-Princeton, Birmingham
Birmingham Surgery Center, Birmingham
Brookwood Medical Center, Birmingham
Children's Hospital, Birmingham
Ginsburg Dermatology Center, Birmingham
Montclair Dermatology, Birmingham
Premier Plastic Surgery Center-AL, Birmingham
Rousso Facial Plastic Surgery, Birmingham
St. Vincent's Hospital, Birmingham
St. Vincent's Hospital Outpatient Surgery, Birmingham
Trinity Medical Center, Birmingham
Veterans Medical Center-GALA, Birmingham
Cullman Regional Medical Center, Cullman
Parkway Medical Center, Decatur
Dothan Surgery Center, Dothan
Flowers Hospital, Dothan
Southeast Alabama Medical Center, Dothan
Southeast Eye Clinic, Dothan
Surgery Center South, Dothan
Medical Center Enterprise, Enterprise
Gulf Health Hospital, Fairhope
South Baldwin Regional Medical Center, Foley
Eliza Coffee Memorial Hospital, Florence
DeKalb Regional Medical Center, Fort Payne
Gadsden Regional Medical Center, Gadsden
Marion Regional Medical Center, Hamilton
Huntsville Hospital, Huntsville
Alabama Outpatient Surgery Center, Jasper
Alabama Orthopaedic Clinic, PC, Mobile
Mobile Infirmary, Mobile
Mobile Surgery Center, Mobile
Springhill Medical Center-Cardio, Mobile
Central Alabama Pain Management Center, Montgomery
Jackson Hospital and Clinic, Montgomery
The Surgery Center, Oxford
Bigelow Cosmetic Surgery Center, Scottsboro
Vaughan Regional Medical Center, Selma
Lanier Health Services, Valley
Brookwood Dermatology, Vestavia Hills
Out of an abundance of caution, the Food and Drug Administration, Centers for Disease Control and Prevention and ADPH have asked health care facilities to notify all individuals for whom they administered an injectable NECC product, including an ophthalmic drug that is injectable or used in conjunction with eye surgery, or a cardioplegic solution after May 21, 2012. The types of procedures include, but are not limited to, epidurals, joint injections, eye surgeries, and heart surgeries.
"Alabama health care facilities have had very limited exposure to NECC products, but individuals who have had certain medical procedures using these specific products are being notified," Dr. Donald Williamson, state health officer, said. "If you have had adverse reactions, contact your health care provider."
Nineteen Alabama residents have received NECC contaminated steroid products from procedures in Tennessee and Florida. If any patients are identified with symptoms suggestive of meningitis or other infections, they should be referred to the appropriate medical provider.
In addition, a report should be made to both FDA MedWatch (1-800-332-1088 or www.fda.gov/medwatch) and to ADPH (1-800-338-7384 or www.adph.org, Meningitis Outbreak).
Patients who had a procedure at one of the identified facilities after May 21, 2012, should self-monitor for at least 3 months following the procedure for the signs and symptoms of an adverse event, meningitis or infection related to their procedure. Symptoms of fungal meningitis are new or worsening headache, fever, sensitivity to light, stiff neck, new weakness or numbness in any part of your body, slurred speech, increased pain, and redness or swelling at your injection site.
Symptoms of joint infections are fever, increased pain, redness, warmth or swelling in the joint that received the injection or at the injection site. Infections at other sites may involve fever, chills, redness, swelling, drainage and pain. If you experience any of these, please contact your primary care provider and the health care facilities that performed the procedure.
To speak to a pharmacist about NECC products, please call FDA Drug Information at 855-543-DRUG (3784).
INFORMATION SOURCE: Alabama Department of Public Health
